Vaccibody AS, has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers.
Vaccibody, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, will conduct development through the end of Phase 1b and Genentech will be responsible for development and commercialization thereafter. The transaction will combine Genentech’s global cancer immunotherapy research, development and commercial leadership with Vaccibody’s targeted DNA-based vaccine platform to realize a potential new treatment paradigm of individualized cancer vaccines.
Under the terms of the agreement, Vaccibody will receive USD 200 million in initial upfront and near-term payments. Additionally, Vaccibody will be eligible to receive up to a further USD 515 million in potential payments and milestones, plus low double-digit tiered royalties on sales of commercialized products arising from the partnership. Following completion of the Phase 1b study, Genentech will have responsibility and bear all costs for clinical, regulatory, manufacturing and commercialization activities.
Through this partnership, Genentech and Vaccibody will progress Vaccibody’s investigational product, VB10.NEO, into clinical trials in the U.S. and in Europe. VB10.NEO, an individualized DNA-based neoantigen vaccine, uniquely targets encoded antigens to antigen presenting cells which are essential for generating potent T cell responses required for cancer therapy. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system.
“It is widely believed that the clinical use of cancer vaccines has been limited by the ability to efficiently present the antigens to the immune system and the limited insight into what constitutes clinically relevant antigens. Vaccibody’s immunotherapy platform has been shown to address those challenges with preclinical and clinical data indicating induction of unique CD4+ and importantly CD8+ tumor-specific T cell responses against selected antigens essential for clinical responses,” said Agnete B. Fredriksen, Co-Founder, President & Chief Scientific Officer of Vaccibody.
Further information on the agreement with Genentech, a member of the Roche Group: https://www.vaccibody.com/vaccibody-enters-into-worldwide-license-and-collaboration-agreement-with-genentech-a-member-of-the-roche-group-to-develop-individualized-neoantigen-cancer-vaccines/
Vaccibody future R&D focus and strategy
The payments and milestones received under the terms of this licensing agreement will enable Vaccibody to accelerate and expand its other internal R&D programs under the Vaccibody technology platform. Vaccibody will focus its R&D efforts on further development of VB10.16 and explore other shared neoantigen cancer vaccines; infectious diseases vaccines and in addition, leverage its in-house expertise and deep know-how to develop novel immunotherapeutic products in new strategic areas.
Further information on Vaccibodys future R&D focus and strategy: https://www.vaccibody.com/vaccibody-announces-update-on-expanded-rd-focus-and-strategy/